Immunogenicity and immune persistence of human rabies vaccine (Vero cell) in healthy people aged 10-17 years
10.3760/cma.j.cn112309-20240618-00218
- VernacularTitle:冻干人用狂犬病疫苗(Vero细胞)在10～17岁健康人群中的免疫原性与免疫持久性研究
- Author:
Zhenzhen LIANG
1
;
Yugang SHEN
;
Xiaosong HU
;
Bo XING
;
Xinpei ZHANG
;
Yingping CHEN
;
Yu MAO
;
Huakun LYU
Author Information
1. 浙江省疾病预防控制中心免疫规划所，杭州 310051
- Publication Type:Journal Article
- Keywords:
Rabies vaccine;
Vero cell;
Minors;
Immune response
- From:
Chinese Journal of Microbiology and Immunology
2025;45(2):135-140
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the immunogenicity and immune persistence of human rabies vaccine (Vero cell) in healthy people aged 10-17 years and compare it with a group of adults aged 18-60 years.Methods:This study was conducted between July 2021 and November 2022 with Shangyu district and Shengzhou city of Shaoxing city, Zhejiang Province selected as the research sites. Zagreb regimen (2-1-1 schedule) and Essen regimen (1-1-1-1-1 schedule) were used for rabies vaccine administration. Serum samples were collected at different time points before and after immunization to compare the differences in seropositivity rates and geometric mean concentrations (GMC) between the 10-17 age group and the 18-60 age group.Results:A total of 1 200 healthy participants aged 10-60 were included, with 157 individuals (13.1%) in the 10-17 age group and 1 043 individuals (86.9%) in the 18-60 age group. Both groups displayed a nearly 100% seropositivity rate at 3, 6 and 12 months, and the participants in the same age group had similar antibody levels. The GMC of antibodies gradually increased after vaccination and peaked on 14 d. The 10-17 age group showed higher GMC of antibodies than the 18-60 age group at 14 d after the first dose (Zagreb regimen: 81.85 IU/ml vs 63.15 IU/ml, t=2.411, P=0.018; Essen regimen: 86.61 IU/ml vs 69.24 IU/ml, t=3.906, P<0.001). Similar differences were observed in the GMC of antibodies at 14 d and 3 months after the full vaccination course, but these differences gradually decreased and disappeared at 6 and 12 months after vaccination. Conclusions:Human rabies vaccine (Vero cell) has lasting immune protection in all participants within one year after vaccination, with no significant differences between the two vaccination regimens. Participants aged 10-17 have higher antibody levels compared to adults aged 18-60, but there is no significant difference in immune persistence between the two age groups.
